Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders.
about
Imatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients.Simple methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib.Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation.Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate.Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III studyAdherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital.Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer.Therapeutic drug monitoring for imatinib: Current status and Indian experience.Clinical efficacy and safety of imatinib in the management of Ph(+) chronic myeloid or acute lymphoblastic leukemia in Chinese patients.Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?Therapeutic drug monitoring in cancer chemotherapy.Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase.Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.Suppression of carboxylesterases by imatinib mediated by the down-regulation of pregnane X receptor.Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growthPractical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels.An Automated Homogeneous Immunoassay for Quantitating Imatinib Concentrations in Plasma.Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients.Mutations in ABL kinase domain are associated with inferior progression-free survival.No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia.Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib.Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour Patients.Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy?
P2860
Q33557847-D6BB9932-887B-456D-9DBD-0746CC990B75Q34377463-85D365E9-D199-4936-9686-499C3BE362F4Q36243653-B6174068-CAF6-49B5-8364-8554B00C2607Q36694926-77A3AF28-6B0E-4720-9C16-929A3C7A2D94Q36933601-8A82B26E-2DBA-453B-9216-868E08224561Q37057014-D6F82C8A-6D32-4B4B-A7A8-7D50395CE684Q37249366-A25C5AE3-F313-433F-942D-5E3566A2417EQ37517632-1E801700-14DC-4958-9C85-DE531774D3E9Q37630453-D92E7F41-9EBA-42EF-BD40-AF1FD38FE003Q37731289-A97265E7-B2D7-47F6-98C9-98F424921B76Q37810220-3ED88823-A629-465C-A06D-DEA8E58EBD80Q37862942-36685858-933D-4258-94D5-BACE6BF7FBA6Q38190857-2D2EC9A1-80D7-4757-8D56-485E3899E39CQ38995804-3EB4E521-B395-40C8-9B2C-4E2CD3607306Q39413595-9B2D9879-B8DC-487A-A7B2-2A213C169E1BQ39429946-23F9A1E1-3F6F-4CDF-B34A-99BA41634C41Q39651800-56F7FBB3-5C91-469A-86C7-26B714EDAF63Q41568738-74931CE2-0A41-4B69-B992-14299F5B9ED6Q42723108-B90A9E4C-00C2-43DD-8ECF-45E573D88ECFQ43109564-EAC70771-1AE6-44BF-A2E1-E7136351693CQ44027139-4B3A8348-63DA-4BF1-A040-1ACBAE7BA173Q47847397-7DC2A945-6C56-41C8-9622-AC950E981A35Q47969048-680AEAB3-F90B-429B-815B-706713A6A94FQ48152547-7E9D09B0-536A-4C87-B757-C334A30CA44CQ48278939-F17788AF-7E24-4C71-89E1-274070BFDBFBQ55002373-ADACF28F-E18A-42D5-BF1B-F957F6D3BC73
P2860
Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Drug monitoring of imatinib le ...... responders and non-responders.
@en
Drug monitoring of imatinib le ...... responders and non-responders.
@nl
type
label
Drug monitoring of imatinib le ...... responders and non-responders.
@en
Drug monitoring of imatinib le ...... responders and non-responders.
@nl
prefLabel
Drug monitoring of imatinib le ...... responders and non-responders.
@en
Drug monitoring of imatinib le ...... responders and non-responders.
@nl
P2093
P1476
Drug monitoring of imatinib le ...... responders and non-responders.
@en
P2093
P2888
P304
P356
10.1007/S00228-009-0621-Z
P577
2009-02-12T00:00:00Z